

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

INNOPHARMA LICENSING, INC., INNOPHARMA LICENSING LLC,
INNOPHARMA INC., INNOPHARMA LLC, MYLAN
PHARMACEUTICALS INC., and MYLAN INC.,
Petitioners,

v.

SENJU PHARMACEUTICAL CO., LTD.,
Patent Owner.

Case IPR2016-00090
Patent 8,871,813 B2

Mailed: November 9, 2015

Before DAVID SCHMERFELD, *Trial Paralegal*.

NOTICE OF FILING DATE ACCORDED TO PETITION
AND
TIME FOR FILING PATENT OWNER PRELIMINARY RESPONSE

The petition for *inter partes* review in the above proceeding has been
accorded the filing date of November 2, 2015.

A review of the petition identified the following defects:

Numerous duplicate exhibits have been uploaded (i.e., 1011, 1020,

1022, 1030, 1038, 1047, and 1050). See 37 C.F.R. § 42.6(d). Also, a copy of Exhibit 1008 is incorrectly filed as Exhibit 1009 under the name “InnoPharma Exhibit 1009” (filing date 11/2/2015). Petitioners may submit a written request to trials@uspto.gov to have the duplicate exhibits expunged specifically identifying the exhibits to be expunged (e.g., by the name given to the exhibit in the Patent Review Processing System (PRPS) and/or by the date the exhibit was filed).

Petitioners must correct the defects within **FIVE BUSINESS DAYS** from this notice. Failure to correct the defects may result in an order to show cause as to why the Board should institute the trial. No substantive changes (e.g., new grounds) may be made to the petition.

Patent Owner may file a preliminary response to the petition no later than three months from the date of this notice. The preliminary response is limited to setting forth the reasons why the requested review should not be instituted. Patent Owner may also file an election to waive the preliminary response to expedite the proceeding. For more information, please consult the Office Patent Trial Practice Guide, 77 Fed. Reg. 48,756 (Aug. 14, 2012), which is available on the Board Web site at <http://www.uspto.gov/PTAB>.

Patent Owner is advised of the requirement to submit mandatory notice information under 37 C.F.R. § 42.8(a)(2) within 21 days of service of the petition.

The parties are encouraged to use the heading on the first page of this Notice for all future filings in the proceeding.

The parties are advised that under 37 C.F.R. § 42.10(c), recognition of counsel *pro hac vice* requires a showing of good cause. The parties are authorized to file motions for *pro hac vice* admission under 37 C.F.R.

Case IPR2016-00090
Patent 8,871,813 B2

§ 42.10(c). Such motions shall be filed in accordance with the “ORDER Authorizing Motion for *Pro Hac Vice* Admission” in Case IPR2013-00639, Paper 7, a copy of which is available on the Board Web site under “Representative Orders, Decisions, and Notices.”

The parties are reminded that unless otherwise permitted by 37 C.F.R. § 42.6(b)(2), all filings in this proceeding must be made electronically in PRPS, accessible from the Board Web site at <http://www.uspto.gov/PTAB>. To file documents, users must first obtain a user ID and password by registering with PRPS. Information regarding how to register with and use PRPS is available at the Board Web site.

If there are any questions pertaining to this notice, please contact David Schmerfeld at 571-272-7184 or the Patent Trial and Appeal Board at 571-272-7822.

PETITIONERS:

Jitendra Malik
jitty.malik@alston.com

Hidetada James Abe
james.abe@alston.com

Lance Soderstrom
lance.soderstrom@alston.com

PATENT OWNER:

WENDEROTH, LIND & PONACK, L.L.P.
1030 15th Street, N.W.,
Suite 400 East
Washington, DC 20005